Earlier quoted context omitted.
Glad to hear that! Some of his thoughts really resonated with me although they run counter to the current corporate research culture. I think Google managed to recreate something similar with their 20% projects
> "recreate" Other companies have had the 15% / 20% culture, etc. long before Google. Example, http://archive.wired.com/techbiz/media/news/1998/01/9858
YC Research
371–380 of 389 posts
Re: YC Research
#372Re: YC Research
#373Reminds me in some way of this tweet from PG last year: > Paul Graham (@pg) — Markets are usually quite clever but one place they break is in encouraging treatments rather than vaccines. Subscription revenue. https://twitter.com/paulg/status/498875418527543297
As someone else already replied, that's an incentive problem. If you change the incentives to "pay $X a month while healthy, pay nothing when sick" then the profit would be in the cure. Unfortunately, we switched from that a while ago (my understanding is that we used to do "pay while healthy" around the 1900s) and now the current way seems "normal".
Beyond that, vaccines are a "Pay $X per month while healthy" treatment - you have to treat everyone whether they're sick or not, and as long as humans keep breeding, you have a replenishing customer base unless we manage the (rare) feat of eradication.
The problem is that modern vaccine targets are hard. Multiple strains, dangerous responses from partial immunity (Dengue), very rapid viral evolution (HIV, flu), etc.
Re: YC Research
#374Earlier quoted context omitted.
As someone else already replied, that's an incentive problem. If you change the incentives to "pay $X a month while healthy, pay nothing when sick" then the profit would be in the cure. Unfortunately, we switched from that a while ago (my understanding is that we used to do "pay while healthy" around the 1900s) and now the current way seems "normal".
Except that tweet isn't really accurate - vaccine research is pretty active, and modern, new vaccines have made their makers a fair bit of money. Beyond that, vaccines are a "Pay $X per month while healthy" treatment - you have to treat everyone whether they're sick or not, and as long as humans keep breeding, you have a replenishing customer base unless we manage the (rare) feat of eradication. The problem is that m…
(like Lyme disease, which had a vaccine pulled, I'm under the impression that it was not pulled for great reasons)
Re: YC Research
#375Earlier quoted context omitted.
Unless YC is promising to fund these researchers for life they'll pretty much have to, or else they'll never get back on the treadmill once the YC money runs out.
That's not true. University professors have sabbaticals, and can also go on extended leave for multiple years and return just fine.
Re: YC Research
#376That's great! Two questions: - Will the researchers need to be based in the Bay Area - AFAIK: not the best place to raise a family? - In the short term, how many researchers do you plan to hire?
Yes, but we're coming in on the very high end of the comp scale. We're also considering doing things like YC guaranteeing 100% mortgages for the researchers--housing prices in the bay area are a joke. We're starting relatively small (on the order of 10) and grow from there at a reasonable rate.
Re: YC Research
#377Earlier quoted context omitted.
How will this research remain bias-free when salaries are being paid for by YC? What happens when some of the research that is done paints some of the activities of YC or their companies in a less-than-positive light?
It's not really that different from work in another corporate research division (IBM, PARC, MSR, Bell Labs..). Even in academia you are still getting paid, and your work is influenced by funding frameworks, citation index and faculty interests. Peer review has long been the traditional validation mechanism in science. I don't see why it wouldn't be applicable here.
Re: YC Research
#378Earlier quoted context omitted.
Except that tweet isn't really accurate - vaccine research is pretty active, and modern, new vaccines have made their makers a fair bit of money. Beyond that, vaccines are a "Pay $X per month while healthy" treatment - you have to treat everyone whether they're sick or not, and as long as humans keep breeding, you have a replenishing customer base unless we manage the (rare) feat of eradication. The problem is that m…
What about stuff that isn't very transmissible person to person? (like Lyme disease, which had a vaccine pulled, I'm under the impression that it was not pulled for great reasons)
Re: YC Research
#379Re: YC Research
#380Earlier quoted context omitted.
> Rely on peers' opinions to measure merit and you just reward back-scratching. Rely on objective measures like citation counts and h-index and you incentivise people to focus on these instead of research quality. In the meantime, Google seems to have developed a pretty good ranking system that is difficult to game.
Don't citation indexes work pretty much exactly like Google's PageRank, with cites taking the place of href links? A parent comment seems to suggest the same thing, so it looks like the ranking is gameable. In practice I understand this happens via citation-swapping (similar to link swapping, or paid links in blogs) and poor-quality journals accepting articles for a fee, or without review (much like paid content, or…
Compare this to the situation in rating of academic research, where the papers are rated by the community of authors itself and the ranking is essentially a weighted counting of references. Of course it leads to lots of self-serving spam.
If the idea of independent raters (and possibly machine learning on top of it) could be implemented for academic papers as well, that would be a big improvement, I think. Academia has got a lot to learn from search engines.